ROCHESTER, MN — Inappropriate dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for atrial fibrillation (AF) was common in a large US cohort study, including inappropriate dosage ...

Bleeding risk with the new oral anticoagulant drugs (NOACs) is increased when they are used with some other medications, including amiodarone, often co-prescribed with these agents, a new study warns.

HOUSTON, TX—There’s no such thing as a good intracranial hemorrhage (ICH), but a new analysis hints that patients who have one might be better off if they’re taking a non-vitamin K antagonist oral ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

Patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants (NOACs) have a heightened risk of major bleeding when also treated with other medications, including ...

Uninterrupted treatment with novel oral anticoagulants during catheter ablation of atrial fibrillation is safe, suggests new research. Continuation of NOAC therapy was not associated with ...

BOSTON -- Lower adherence to non-vitamin K antagonist oral anticoagulant (NOACs) might wipe out the advantage over warfarin (Coumadin), according to a large real-world observational study. In an ...

(HealthDay News) — Non-vitamin K antagonist oral anticoagulants (NOACs) have been adopted into practice and are more frequently prescribed than vitamin K antagonists (VKAs) in the Global Registry on ...